# Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio

> **NCT03178084** · PHASE3 · COMPLETED · sponsor: **Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal** · enrollment: 721 (actual)

## Conditions studied

- HIV/AIDS

## Interventions

- **DRUG:** Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID
- **DRUG:** Efavirenz QD + Zidovudine/Lamivudine BID
- **DRUG:** Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD

## Key facts

- **NCT ID:** NCT03178084
- **Lead sponsor:** Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-15
- **Primary completion:** 2016-11-05
- **Final completion:** 2017-03-07
- **Target enrollment:** 721 (ACTUAL)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03178084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03178084, "Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03178084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*